JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47

Benzinga · 5d ago
JP Morgan analyst Brian Cheng maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and raises the price target from $46 to $47.